Breaking News Instant updates and real-time market news.

FGEN

FibroGen

$41.61

3.59 (9.44%)

, AZN

AstraZeneca

$47.25

0.46 (0.98%)

19:12
11/10/19
11/10
19:12
11/10/19
19:12

Piper Jaffray sees approval for FibroGen's roxadustat, but still has concerns

Piper Jaffray analyst Danielle Brill maintained a Neutral rating and $42 price target on FibroGen (FGEN). After getting more color on the MACE data from a meeting with management, speaking to a lead investigator, and listening to AstraZeneca's (AZN) call, Brill continues to expect approval of the drug, but also sees aspects that will drive debate, and a lack of clarity until FDA briefing documents for an Ad Com panel are released next year, which could be 6-10 months from now depending on priority. The analyst also still questions whether the labeling for the drug, if it is approved, will include a black box safety warning.

FGEN

FibroGen

$41.61

3.59 (9.44%)

AZN

AstraZeneca

$47.25

0.46 (0.98%)

  • 11

    Nov

  • 18

    Nov

  • 07

    Dec

FGEN FibroGen
$41.61

3.59 (9.44%)

06/17/19
PIPR
06/17/19
NO CHANGE
PIPR
Piper says buy Akebia before market figures out competitive positoin
After hosting an investor call with Akebia Therapeutics (AKBA) CEO John Butler, Piper Jaffray analyst Christopher Raymond thinks vadadustat's competitive position relative to FibroGen's (FGEN) roxadustat is "stronger, not weaker now." As such, the analyst recommends buying shares of Akebia "before the market begins to figure this out." Raymond left the call incrementally confident in vadadustat "on a number of levels," namely its approvability given Akebia's alignment with FDA on trial design and statistical analysis. He keeps an Overweight rating on the shares with a $22 price target.
07/24/19
HCWC
07/24/19
NO CHANGE
Target $19
HCWC
Buy
Akebia shares at 'excellent entry point,' says H.C. Wainwright
After Akebia (AKBA) announced that its Japanese partner on vadadustat has submitted a New Drug Application in Japan that supports approval for anemia due to chronic kidney disease in both non-dialysis and dialysis patients, H.C. Wainwright analyst Ed Arce noted that this represents the first regulatory submission for vadadustat. The current valuation, with shares trading near 52-week lows, presents "an excellent entry point" given that the primary bear thesis depends on the first-to-market advantage of Fibrogen's (FGEN) roxadustat, which Arce views as "fundamentally flawed," he tells investors. In light of the JNDA submission, as well as the current timeline, Arce pushed back his U.S. and EU market launch and initial sales estimates to early 2022 and trimmed his price target on Akebia shares to $19 from $21, but he keeps a Buy rating on the stock.
11/05/19
SBSH
11/05/19
NO CHANGE
Target $65
SBSH
Buy
FibroGen short report brings buying opportunity, says Citi
Citi analyst Joel Beatty believes yesterday's 8% stock price decline caused by a short report provides a good buying opportunity for FibroGen ahead of the Phase 3 Roxadustat results to be presented this Friday. The analyst continues to believe the FDA would be willing to approve Roxadustat based on the totality of the MACE data despite the lack of proven MACE non-inferiority. He keeps a Buy rating on FibroGen with a $65 price target.
AZN AstraZeneca
$47.25

0.46 (0.98%)

09/03/19
09/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boston Beer (SAM) downgraded to Underperform from Hold at Jefferies with analyst Kevin Grundy saying his consumer survey and web scrapes point to the potential for greater competitive intensity in the "rapidly growing" spiked seltzer category. He views Boston Beer's valuation as "stretched" given its competitive risk in hard seltzers. 2. Spirit Airlines (SAVE) downgraded to Outperform from Strong Buy at Raymond James with analyst Savanthi Syth now expecting a delay in the inflection of sentiment to early 2020. 3. AstraZeneca (AZN) downgraded to Sell from Hold at DZ Bank. 4. Heico (HEI) downgraded to Sell from Neutral at UBS with analyst Louis Raffetto citing valuation. 5. Hilton (HLT) downgraded to Neutral from Outperform at Macquarie with analyst Chad Beynon saying he believes the stock's current valuation with near-peak EBITDA multiples prices in the positives while the company faces a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
Neutral
Competitor PARP data an incremental negative for Clovis, says JPMorgan
JPMorgan analyst Cory Kasimov said he views the Phase 3 data presented by AstraZeneca (AZN) and Merck (MRK) on their PARP inhibitor Lynparza in previously treated prostate cancer as incrementally negative to Clovis (CLVS), which has "a lot riding on the prostate indication" since its Rubraca is "neck-and-neck with the competition to be first to market." While there wasn't anything bad reported at the ESMO meeting from Clovis' own prostate update, AstraZeneca "looks primed to come to market with a much more robust data set" and Clovis may "be playing catch-up" in another cancer indication, said Kasimov, who keeps a Neutral rating on Clovis shares.
10/28/19
GUGG
10/28/19
INITIATION
Target $44
GUGG
Buy
Guggenheim starts Viela Bio at Buy, makes stock Best Idea
Guggenheim analyst Seamus Fernandez initiated coverage of Viela Bio with a Buy rating and $44 price target. The analyst makes the stock his Best Idea, seeing a potential path to a three-to-five times return over the next five years. Viela is a "uniquely compelling" biotech investment opportunity for several reasons, including a senior leadership team with deep biopharma roots, the unique spinout origin story from AstraZeneca (AZN), and large total addressable markets across various autoimmune diseases, Fernandez tells investors in a research note. With five biologic assets including inebilizumab already filed with the FDA, Viela "is well on its way to being a fully integrated biotechnology company focused on autoimmune disease," contends the analyst.
11/05/19
JEFF
11/05/19
NO CHANGE
Target $75
JEFF
Buy
Jefferies sees nothing new in FibroGen short report
Jefferies analyst Michael Yee does not see "anything really new" in yesterday's short report on FibroGen. The report is all based on earlier small Phase II/III studies that are already known, as well as on studies in China/Japan, where the drug has recently been approved, Yee tells investors in a research note. Moreover, FibroGen partner AstraZeneca (AZN) has publicly stated it is comfortable with the data, adds Yee. He keeps a Buy rating on FibroGen shares with a $75 price target

TODAY'S FREE FLY STORIES

QGEN

Qiagen

$37.48

0.175 (0.47%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Hot Stocks
Breaking Hot Stocks news story on Qiagen »

Qiagen trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/15/19
11/15
15:17
11/15/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/15/19
11/15
15:16
11/15/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.46

2.48 (1.89%)

15:00
11/15/19
11/15
15:00
11/15/19
15:00
Periodicals
Oklahoma judge cuts J&J payment due in opioid case to $465M, Reuters reports »

An Oklahoma judge has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

EA

Electronic Arts

$97.88

0.34 (0.35%)

14:59
11/15/19
11/15
14:59
11/15/19
14:59
Periodicals
EA, BioWare planning complete revamp of 'Anthem,' Kotaku says »

Video game developer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

F

Ford

$8.95

0.15 (1.70%)

, GM

General Motors

$36.92

0.12 (0.33%)

14:56
11/15/19
11/15
14:56
11/15/19
14:56
Periodicals
States sue EPA for right for stricter emission regulations, Washington Post says »

California, along with 23…

F

Ford

$8.95

0.15 (1.70%)

GM

General Motors

$36.92

0.12 (0.33%)

HMC

Honda

$29.01

0.175 (0.61%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$144.15

1.02 (0.71%)

TSLA

Tesla

$350.80

1.29 (0.37%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.03

0.05 (0.31%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 09

    Dec

  • 04

    Feb

MDLZ

Mondelez

$52.71

-0.19 (-0.36%)

14:52
11/15/19
11/15
14:52
11/15/19
14:52
Hot Stocks
Mondelez recalls Cheese Nips in U.S. due to potential presence of plastic pieces »

Mondelez Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLM

Columbia Sportswear

$93.21

-1.28 (-1.35%)

14:50
11/15/19
11/15
14:50
11/15/19
14:50
Conference/Events
Columbia Sportswear participates in a conference call with Wedbush »

Footwear & Apparel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

14:47
11/15/19
11/15
14:47
11/15/19
14:47
Conference/Events
Wedbush hardware/component analyst to hold an analyst/industry conference call »

Hardware & Component…

NVS

Novartis

$89.84

0.32 (0.36%)

14:43
11/15/19
11/15
14:43
11/15/19
14:43
Hot Stocks
Novartis receives FDA approval for BLA for Adakveo injection »

The FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ALNA

Allena Pharmaceuticals

$1.61

-0.03 (-1.83%)

14:39
11/15/19
11/15
14:39
11/15/19
14:39
Conference/Events
Wedbush emerging pharma analyst to hold an analyst/industry conference call »

Emerging Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$138.00

3.53 (2.63%)

, CYH

Community Health

$2.95

0.075 (2.61%)

14:38
11/15/19
11/15
14:38
11/15/19
14:38
Hot Stocks
Hospital stocks up after Trump reveals healthcare price transparency proposal »

Shares of several…

HCA

HCA Healthcare

$138.00

3.53 (2.63%)

CYH

Community Health

$2.95

0.075 (2.61%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$142.53

1.36 (0.96%)

THC

Tenet

$29.91

0.44 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$23.69

2.2 (10.24%)

14:28
11/15/19
11/15
14:28
11/15/19
14:28
Recommendations
Amarin analyst commentary  »

Amarin price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

VIA

Viacom

$26.63

1.32 (5.22%)

, VIAB

Viacom

$23.20

0.72 (3.20%)

14:25
11/15/19
11/15
14:25
11/15/19
14:25
On The Fly
Box Office Battle: 'Ford v Ferrari' seen topping 'Charlie's Angels' this weekend »

Welcome to "Box Office…

VIA

Viacom

$26.63

1.32 (5.22%)

VIAB

Viacom

$23.20

0.72 (3.20%)

FOX

Fox Corp.

$33.85

0.39 (1.17%)

FOXA

Fox Corp.

$34.51

0.29 (0.85%)

T

AT&T

$39.28

0.315 (0.81%)

DIS

Disney

$144.95

-2.24 (-1.52%)

CMCSA

Comcast

$44.61

-0.86 (-1.89%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$9.76

0.41 (4.39%)

LGF.B

Lionsgate

$9.15

0.43 (4.93%)

SNE

Sony

$62.10

0.3 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

AZN

AstraZeneca

$47.18

-0.19 (-0.40%)

14:25
11/15/19
11/15
14:25
11/15/19
14:25
Options
AstraZeneca call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

14:25
11/15/19
11/15
14:25
11/15/19
14:25
General news
Treasury Action: Treasuries remain slightly weaker »

Treasury Action:…

GOOG

Alphabet

$1,328.60

16.41 (1.25%)

, GOOGL

Alphabet Class A

$1,327.62

17.83 (1.36%)

14:20
11/15/19
11/15
14:20
11/15/19
14:20
Hot Stocks
Supreme Court to consider Google appeal of Oracle copyright case »

The U.S. Supreme Court…

GOOG

Alphabet

$1,328.60

16.41 (1.25%)

GOOGL

Alphabet Class A

$1,327.62

17.83 (1.36%)

ORCL

Oracle

$56.42

0.32 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/15/19
11/15
14:17
11/15/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,748.38

-6.33 (-0.36%)

14:16
11/15/19
11/15
14:16
11/15/19
14:16
Periodicals
John Lynch leaving Amazon Studios, Variety reports »

Amazon Studios head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/15/19
11/15
14:16
11/15/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$243.22

2.82 (1.17%)

14:12
11/15/19
11/15
14:12
11/15/19
14:12
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$74.07

0.215 (0.29%)

14:05
11/15/19
11/15
14:05
11/15/19
14:05
Hot Stocks
Citi reports October credit loss 2.61% vs. 2.61% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

GOOG

Alphabet

$1,326.95

14.76 (1.12%)

, GOOGL

Alphabet Class A

$1,325.85

16.06 (1.23%)

13:55
11/15/19
11/15
13:55
11/15/19
13:55
Periodicals
Google cancels weekly TGIF meetings, CNBC reports »

Google is dropping TGIF,…

GOOG

Alphabet

$1,326.95

14.76 (1.12%)

GOOGL

Alphabet Class A

$1,325.85

16.06 (1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
11/15/19
11/15
13:55
11/15/19
13:55
General news
Action Economics Survey results: »

Action Economics Survey…

EW

Edwards Lifesciences

$244.30

3.9 (1.62%)

13:39
11/15/19
11/15
13:39
11/15/19
13:39
Periodicals
Edwards recalling Pascal guide sheaths, Mass Device reports »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.